**Right Care Heart Disease, Stroke and Diabetes Prevention and Management Continuing Medical Education (On-Demand & Complementary)**

**Women’s CVD Part 3: Right Care Heart Attack & Stroke Prevention (11.18.24): Heart Failure Management & Cardiac Disease in Pregnancy**

January 22, 2025 – December 31, 2025

**Purpose**

Over a period of seventeen years, we have collaboratively built this program with experts and physician leaders across the State of California. The need for quality improvement to prevent heart attacks, strokes, and diabetes is expressed in our California Right Care Initiative project brief (attached).

This module is an overview of heart failure epidemiology and guideline directed medical therapy and a review of cardiac disease in pregnancy. The live lecture for this recording took place November 18, 2024.

**Target Audience**

Specialties – Emergency Medicine, Family Medicine, Medicine, Neurology, Obstetrics & Gynecology, Radiological Sciences, Cardiology, General Internal Medicine & Primary Care, Pulmonary Diseases & Critical Care Medicine, Rheumatology

Professions – Physician, Non-Physician, Medical Assistant, Medical Student, Nurse, Nurse Practitioner, Pharmacist, Pharmacy Technician, Physician Assistant, Registered Dietitian, Resident Physician, Social Worker

**Activity Objectives**

1 1) Outline heart failure epidemiology, classification and up-to-date guideline directed medical therapy.

2 2) Recognize cardiac considerations in pregnancy, implement risk stratification tools, and preconception counseling.

3 3) Understand cardiac complications of pregnancy and future implications.

**Accreditation Statement**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California, Irvine School of Medicine and UC Berkeley, Right Care Initiative. The University of California, Irvine School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

**Designation Statement**

The University of California, Irvine School of Medicine designates this Enduring Material for a maximum of 0.50 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**California Assembly Bill 1195 and 241**

This activity is in compliance with California Assembly Bill 1195 and 241, which require CME activities with patient care components to include curriculum in the subjects of cultural and linguistic competency & implicit bias. It is the intent of AB 1195 and AB 241 to encourage physicians and surgeons, CME providers in the State of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population and reduce health disparities through appropriate professional development. Please see the CME website, <https://www.meded.uci.edu/CME/> for AB 1195 and AB 241 resources.



ABIM
CME
MOC
Accredited

CME for
ABPath CC

Part 2
MOC
The American Board of Pediatrics

**Faculty & Planner Disclosures**

University of California, Irvine School of Medicine Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Sarah Epstein, PhD | Other Planning Committee Member | Nothing to disclose - 10/23/2024 |
| Hattie Hanley, Other | Course Director | Nothing to disclose - 10/23/2024 |
| Karen M Sky, MD, FACP, FACR | Activity Administrator, Activity Coordinator | Nothing to disclose - 10/23/2024 |
| Nathan D. Wong, PhD, MPH | Other Planning Committee Member | Grant or research support-Novartis Corporation Pharmaceuticals|Consulting Fee-Novartis Corporation Pharmaceuticals|Consulting Fee-Amgen, Inc.|Consulting Fee-Ionis Pharmaceuticals|Grant or research support-Novo Nordisk (Any division) (Relationship has ended)|Consulting Fee-Heart Lung|Grant or research support-Amgen, Inc.|Speakers Bureau-Novartis Corporation Pharmaceuticals - 01/06/2025 |
| Jan Hirsch, PhD | Other Planning Committee Member | Nothing to disclose - 10/23/2024 |
| William Bommer, MD | Other Planning Committee Member | Nothing to disclose - 10/23/2024 |
| Brian Wong, MD, PhD | Other Planning Committee Member | Nothing to disclose - 01/16/2025 |

**Agenda**

**[INSERT AGENDA HERE MANUALLY]**

**Acknowledgement of Commercial Support**

No commercial support has been received for this activity.